

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 1 310 243 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
14.05.2003 Bulletin 2003/20

(51) Int Cl.7: A61K 9/00, A61K 31/58,
A61K 9/10, A61P 11/02

(21) Application number: 02028325.5

(22) Date of filing: 28.11.1997

(84) Designated Contracting States:
AT CH DE DK FI GB IT LI LU MC PT SE

(30) Priority: 05.12.1996 SE 9604486
29.04.1997 US 846960

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
97948065.4 / 0 907 365

(71) Applicant: AstraZeneca AB
151 85 Södertälje (SE)

(72) Inventors:
• Santesson, Gordon
242 34 Hörby (SE)
• Nilsson, Hans
221 87 Lund (SE)

Remarks:

This application was filed on 17 - 12 - 2002 as a
divisional application to the application mentioned
under INID code 62.

(54) Novel formulation

(57) A new metered unit dose comprising 32 µg of budesonide is disclosed as well as a formulation thereof and
the use thereof for the treatment of conditions in the nose.

EP 1 310 243 A1

Description**Field of the Invention**

5 [0001] The present invention relates to a new unit dose of budesonide, a formulation thereof, and its use for the treatment of conditions of the nose.

Background of the Invention

10 [0002] Glucocorticosteroids are widely used for the treatment of seasonal allergic as well as perennial rhinitis. Intra-nasal glucocorticosteroids reduce inflammation of the nasal mucosa including edema. In addition, they are known to suppress the recruitment of polymorphonuclear and mononuclear cells, cytokine production, and, during maintenance treatment, both early and late-phase nasal reactions.

15 [0003] One of the glucocorticosteroids known for intranasal use is budesonide, 16 α ,17 α -butylienedioxy-11 β ,21-dihydroxypregna-1,4-diene-3,20-dione.

20 [0004] Initially solid budesonide was used in pressurized metered dose inhaler (pMDI) preparations for intranasal administration, suitably dispensed from a specially adapted nasal inhaler. A recommended maximum daily metered dose of budesonide has been 400 μ g. Later on a nasal spray preparation for delivery from a spray device was prepared, containing budesonide in the form of an aqueous suspension. The same maximum daily metered dose as for the pMDI preparation was recommended. A third formulation is a dry powder formulation.

25 [0005] Both the nasal pMDI inhaler device and the aqueous nasal spray device are constructed to dispense a defined unit dose at each actuation. For example, a metered unit dose of 50 μ g has a recommended administration regime of one dose per nostril, four times daily, yielding a total of eight 50 μ g metered doses per day. Alternatively, a metered unit dose of 100 μ g would provide the same total metered daily dose (400 μ g) if administered to each nostril twice daily, for a total of four 100 μ g metered doses per day.

30 [0006] We have now surprisingly found that a lower metered unit dose of budesonide than that previously used can be administered safely and effectively to the nose.

Disclosure of the invention

35 [0007] According to the invention we provide a metered unit dose of a therapeutic composition comprising budesonide in therapeutically effective amount that is less than about 40 μ g, said composition being suitable for nasal administration to a mammal in a single dose.

40 [0008] Preferably, the metered unit dose comprises from about 16 to about 40 μ g of budesonide. In a preferred embodiment of the invention, the metered unit dose comprises about 32 μ g of budesonide.

45 [0009] With this new lower metered unit dose, it is possible for the patient to take a lower metered daily dose, while still maintaining efficacy. The new lower unit dose is also convenient for the patient. Surprisingly, metered daily doses of 256 μ g and 400 μ g, delivered by nasal spray, were found to be equally efficacious. A metered daily dose of 256 μ g can be obtained with a metered unit dose of 32 μ g budesonide, dispensed 8 times daily (two doses in each nostril, twice a day). Once the patient has achieved relief using a daily dose of 256 μ g (this may be achieved in from 12 hours to 7 days from the initiation of treatment depending on the patient and the severity of the condition) the daily dose may be reduced to 128 μ g, preferably administered as two doses in each nostril once a day and preferably in the morning. In certain circumstances the daily dose may be reduced even further, e.g. to 64 μ g, by administering one dose to each nostril once a day, again preferably in the morning.

50 [0010] A suitable pharmaceutical formulation of budesonide is a suspension of micronised budesonide in an aqueous vehicle.

55 [0011] Thus, the invention comprises a metered unit dose of a therapeutic composition suitable for nasal administration to a mammal in a single dose, comprising 32 μ g of budesonide and wherein the budesonide is in the form of finely divided particles and is suspended in an aqueous medium with a pH in the range 3.5 to 5.0

[0012] In a further aspect the invention comprises a suspension, preferably an aqueous suspension, comprising from about 0.6 to about 0.7 mg/ml (i.e. from about 0.06 to about 0.07% w/w) of budesonide.

[0013] In yet a further aspect the invention comprises a method of treating conditions of the nose of mammals by administering thereto a metered unit dose of 40 μ g or less of budesonide.

[0014] Conditions that can be treated according to the invention include

- seasonal allergic rhinitis, i.e. pollinosis caused by pollens from ragweed, birch, grass, cedar or other plants
- perennial allergic rhinitis caused by e.g. dust mites (*Dermatophagoides pteronyssinus* and *D. farinae*), cockroaches and mammals such as cats, dogs and horses

- perennial non-allergic rhinitis
- nasal polyps, as well as prevention of post surgical nasal polyps
- chronic sinusitis
- recurrent sinusitis.

5

[0015] In order to form a stable suspension with a minimal tendency to agglomerate or form a sediment, a thickening agent may be included in the formulation. Examples of suitable thickening agents are microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, carbomer, guar gum and hydroxypropyl cellulose. The thickening agent may be present at about 0.1 to 3.0% w/w of the formulation. Preferably microcrystalline cellulose and sodium carboxymethyl cellulose are present at about 0.5 to 2.5%, xanthan gum at about 0.3 to 3%, carbomer at about 0.1 to 2%, guar gum at about 0.3 to 2% and hydroxypropyl methyl cellulose at about 0.5 to 3.0%, w/w of the formulation.

10

[0016] Agents which make the suspension isotonic may be added. Examples are dextrose, glycerin, mannitol, sodium chloride and potassium chloride.

15

[0017] To obtain an efficient dispersion of the budesonide particles in the suspension, a surfactant may be used. Examples of suitable surfactants are Polysorbate 80 (Tween 80) as well as other polyoxyethylene sorbitan fatty acid esters, poloxamers, polyoxyethylene alkyl ethers and polyoxyethylene castor oil derivatives. The surfactant may be present at about 0.005 to 2% w/w of the formulation. We prefer the polyoxyethylene sorbitan fatty acid esters to be present at about 0.005 to 0.5%, poloxamers at about 0.01 to 2%, and polyoxyethylene alkyl ethers or the polyoxyethylene castor oil derivatives at about 0.01 to 1.0%, w/w of the formulation.

20

[0018] We also prefer the formulation to contain a suitable chelating agent, e.g. disodium edetate (EDTA). The chelating agent may be present at about 0.005 to 0.1% w/w of the formulation.

25

[0019] A preservative agent may be added to protect the formulation from microbial contamination. Examples of suitable preservatives are benzalkonium chloride, methylparaben, propylparaben, potassium sorbate and sodium benzoate. The preservative may be present at about 0.002 to 0.5% w/w of the formulation. Preferably benzalkonium chloride is present at about 0.002 to 0.02%, methylparaben at about 0.05 to 0.25%, propylparaben at about 0.01 to 0.2%, potassium sorbate at about 0.5 to 0.2%, and sodium benzoate at about 0.1 to 0.5%, w/w of the formulation.

30

[0020] The pH of the suspension may be adjusted as required. Examples of suitable pH regulating agents are strong mineral acids, e.g. hydrochloric acid. Alternatively, the pH of the system can be adjusted by balancing the acid and salt forms of preservative and chelating agent. We prefer the formulation to have a pH in the range 3.5 to 5.0, more preferably 4.0 to 4.8, and most preferably from about 4.2 to 4.6.

35

[0021] The suspension medium is made essentially of purified water (as describe in the European Pharmacopoeia and the United States Pharmacopoeia), e.g. water for injection.

40

[0022] In the suspension the active constituent budesonide is present as small particles, where at least 90% of the small particles have a mass equivalent sphere diameter of less than 20 μm , preferably at least 80% less than 10 μm and most preferably at least 80% less than 7 μm .

45

[0023] The new unit dose can suitably be dispensed from the above mentioned specially adapted nasal inhaler or spray device. Other means for administration include a simple drop pipette or a rhinyl. Pre-compression metered-dose spray pumps with dose volumes from 25 μl to 150 μl can be used, whereby the concentration of budesonide in the suspension is adjusted to give the desired unit dose of budesonide. Monospray or a bispray pump can be used; for the latter, the recommended unit dose is sequentially delivered into each nostril, for a total metered dose per administration of less than 80 μg budesonide.

50

[0024] According to a further feature of the invention we also provide a therapeutic method of treating or preventing conditions of the upper respiratory tract, the method comprising metering into a nostril of a mammal a unit dose of budesonide, wherein said metered unit dose comprises budesonide in a therapeutically effective amount that is less than about 40 μg .

[0025] The metered amount of budesonide is preferably less than about 320 μg per day, delivered as 8 or more unit doses each dose comprising budesonide in an amount that is less than about 40 μg .

According to a yet further feature of the invention we provide a container containing budesonide and adapted to deliver a unit dose or a formulation according to the invention.

55

[0026] The invention will now be described more in detail in the following non-limiting examples.

EXAMPLE 1

[0027] A unit dose comprising a suspension of 32 μg budesonide in water was prepared by mixing the following ingredients:

Ingredient	(mg)
Budesonide, micronised	0.032
Microcrystalline cellulose and carboxymethylcellulose Sodium (Avicel)	0.625
Dextrose, anhydrous	2.375
Polysorbate 80	0.008
Eddate disodium	0.005
Potassium sorbate	0.060
Hydrochloric acid	to pH 4.5
Purified water	to 50 µl (approx. 47.9 mg added)

EXAMPLE 2

[0028] A 200 litre bulk suspension, which corresponds to approximately 23,000 containers with 120 doses (32 µg/dose) of budesonide each, was prepared by mixing the following ingredients:

Ingredient	Amount (kg)
Budesonide, micronised	0.128
Microcrystalline cellulose and carboxymethylcellulose Sodium (Avicel)	2.500
Dextrose, anhydrous	9.500
Polysorbate 80	0.032
Eddate disodium	0.020
Potassium sorbate	0.240
Hydrochloric acid	to pH 4.5
Purified water	to 204.2

Claims

1. A metered unit dose of a therapeutic composition suitable for nasal administration to a mammal in a single dose, comprising 32µg of budesonide and wherein the budesonide is in the form of finely divided particles and is suspended in an aqueous medium with a pH in the range 3.5 to 5.0
2. A unit dose according to claim 1 in which the pH is 4.0 to 4.8.
3. A unit dose according to claim 1 in which the pH is 4.2 to 4.6.
4. A formulation comprising a suspension of about 0.6 to about 0.7 mg/ml of finely divided budesonide in water.
5. A unit dose according to any one of claims 1 to 3 or a formulation according to claim 4, further comprising a pharmaceutically acceptable thickening agent, isotonicity agent, surfactant, chelating agent, or preservative.
6. A unit dose according to any one of claims 1 to 3 and 5, or a formulation according to claim 4 or 5, wherein the mass equivalent sphere diameter of the budesonide is 10 µm or less.
7. Use of a unit dose or of a formulation according to any one of the preceding claims in the preparation of a pharmaceutical for treating or preventing conditions of the upper respiratory tract by nasal administration.
8. Use according to claim 7, in which the condition is seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, chronic sinusitis, recurrent sinusitis or nasal polyps.
9. Use according to claim 7 or 8, wherein the budesonide is to be metered into the nose of a mammal at a dose of 320 µg, or less, per day, delivered as 8 or more unit doses, wherein each unit dose comprises budesonide in an

metered amount that is less than 40 µg.

10. Use according to claim 9, wherein the amount of budesonide is about 256 µg per day.
- 5 11. A container containing budesonide and adapted to deliver a unit dose according to any one of claims 1 to 3, or 5 or 6 or a formulation according to any one of claims 4 to 6.

10

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 02 8325

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 3 992 534 A (BRATTSAND RALPH LENNART ET AL) 16 November 1976 (1976-11-16) * claims 1,9,17,18,27,32,39 * ---	1-11	A61K9/00 A61K31/58 A61K9/10 A61P11/02
P,X	WO 97 01341 A (MCNEIL PPC INC) 16 January 1997 (1997-01-16) * page 4, line 32 - line 37 * * page 8, line 15 - line 16 * * claims 1,6 * ---	1-11	
P,X	EP 0 780 127 A (PROCTER & GAMBLE) 25 June 1997 (1997-06-25) * page 2, line 57 * * page 3, line 5 - line 20 * -----	1-11	
TECHNICAL FIELDS SEARCHED (Int.Cl.7)			
A61K			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search		Examiner
MUNICH	12 March 2003		Hedegaard, A
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 02 8325

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-03-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 3992534	A	16-11-1976	SE	378110 B	18-08-1975
			AU	5525273 A	07-11-1974
			BE	799728 A1	17-09-1973
			CA	1003402 A1	11-01-1977
			CY	1012 A	23-11-1979
			DE	2323216 A1	29-11-1973
			DK	133249 B	12-04-1976
			FI	50711 B	01-03-1976
			FR	2185406 A1	04-01-1974
			GB	1428416 A	17-03-1976
			HK	49079 A	27-07-1979
			IL	42154 A	31-12-1976
			JP	975395 C	19-10-1979
			JP	49041379 A	18-04-1974
			JP	54007794 B	10-04-1979
			KE	2969 A	20-07-1979
			NL	7306979 A ,B,	21-11-1973
			SU	468408 A3	25-04-1975
			US	3928326 A	23-12-1975
			US	3996359 A	07-12-1976
			ZA	7302956 A	24-04-1974
<hr/>					
WO 9701341	A	16-01-1997	AU	6290396 A	30-01-1997
			WO	9701341 A1	16-01-1997
<hr/>					
EP 0780127	A	25-06-1997	EP	0780127 A1	25-06-1997
<hr/>					